Insider Transactions Reported by 27 Insiders of Spyre Therapeutics, Inc.

Symbol: SYRE on Nasdaq
Location: Waltham, MA

Quick Takeaways

SYRE - Spyre Therapeutics, Inc. has 27 insiders with reported activity on this page.
Net insider value flow over the last year: -$4,979,326.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: ; sell value: $4,979,326.
Net share flow: -156,386.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$4,979,326.

Buys

Shares: 0

Insiders: 0

Sells

$4,979,326

Shares: 156,386

Insiders: 3

Net

-$4,979,326

Shares: -156,386

Insiders: -3

Window (months)	Sell shares	Buy $	Sell $	Net $
0-3	62,958	$0	$2,734,419	-$2,734,419
3-6	75,000	$0	$1,945,267	-$1,945,267
6-9	18,428	$0	$299,639	-$299,639
9-12	0	$0	$0	$0

Spyre Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Cameron Turtle	Chief Executive Officer, Director	$31,326,796	-$3,810,091	-11%	Filing P/S	01 Apr 2026
Michael Thomas Henderson	Director	$5,523,583			Mixed	21 Jan 2026
Scott L. Burrows	Chief Financial Officer	$4,897,740	-$771,335	-14%	Filing P/S	01 Apr 2026
Jeffrey W. Albers	Director	$1,005,838			Filing P/S	29 May 2025
Anthony G. Quinn	President & CEO, Director	$579,952			Mixed	16 Mar 2022
Marcio Souza	Director	$63,900			Mixed	25 Aug 2022
Sheldon Sloan	Chief Medical Officer	$0	-$397,900	-100%	Mixed	01 Apr 2026
Jeff Marc Goldberg	President and CEO, Director				Mixed	29 Nov 2022
Russell J. Cox	Director				Mixed	22 Jun 2023
BAKER BROS. ADVISORS LP	Director				Mixed	08 Jun 2021
Armen Shanafelt	Director				Mixed	07 Jun 2022
Jonathan Alspaugh	President and CFO				Mixed	22 Jun 2023
Hunter C. Smith	Director				Mixed	22 Jun 2023
Jr. Michael Conick Hanley	Chief Business Officer				Mixed	23 Feb 2023
Leslie Sloan	Chief Operating Officer				Mixed	23 Aug 2022
Alison Frances Lawton	Director				Mixed	22 Jun 2023
Sandesh Mahatme	Director				Mixed	07 Jun 2022
Ivana Magovcevic-Liebisch	Director				Mixed	22 Jun 2023
Steven Weber	VP, Controller&Princ Acctg Off				Mixed	17 Feb 2022
James Paul Kastenmayer	General Counsel				Mixed	23 Feb 2023
Bryan Lawlis V	Director				Mixed	07 Jun 2022
Linda L. Neuman	Chief Medical Officer				Mixed	23 Feb 2023
Sandra Milligan	Director				Mixed	29 May 2025
Fairmount Funds Management LLC	Director				Mixed	29 May 2025
Heidy King-Jones	Chief Legal Officer and Corporate Secretary				Mixed	09 Jan 2026
Mark C. McKenna	Director				Mixed	29 May 2025
Laurie Stelzer	Director				Mixed	29 May 2025

Top shareholders of Spyre Therapeutics, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FMR LLC	13F	Company	15%	11,638,819	$381,287,711	—	31 Dec 2025	13F
BlackRock, Inc.	13F 13D/G	Company	6.6% from 13D/G	5,522,101	$180,904,030	—	31 Dec 2025	13F 13D/G
RTW INVESTMENTS, LP	13F 13D/G	Company	6.2% from 13D/G	4,171,996	$136,674,589	—	31 Dec 2025	13F 13D/G
Fairmount Funds Management LLC	13D/G 3/4/5 13F	Peter Evan Harwin · Director · Company	10%	8,106,882	$136,033,480	$0	15 Oct 2025	13D/G 3/4/5 13F
VANGUARD GROUP INC	13F	Company	5.1%	4,035,074	$132,189,024	—	31 Dec 2025	13F
VR Adviser, LLC	13F	Company	4.7%	3,685,448	$120,735,276	—	31 Dec 2025	13F
Capital International Investors	13F	Company	4.4%	3,492,541	$114,415,643	—	31 Dec 2025	13F
PERCEPTIVE ADVISORS LLC	13F 13D/G	Company	4.4% from 13D/G	3,069,225	$100,547,811	—	31 Dec 2025	13F 13D/G
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	3.7%	2,882,420	$94,428,079	—	31 Dec 2025	13F
Commodore Capital LP	13F	Company	3%	2,388,245	$78,238,906	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	2.9%	2,262,839	$74,130,606	—	31 Dec 2025	13F
TCG Crossover Management, LLC	13F	Company	2.4%	1,900,582	$62,263,066	—	31 Dec 2025	13F
TANG CAPITAL MANAGEMENT LLC	13D/G 13F	Company	2.4%	1,892,200	$62,064,160	-$42,895,840	31 Dec 2025	13D/G 13F
JANUS HENDERSON GROUP PLC	13F	Company	2.3%	1,829,009	$59,918,335	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	2.1%	1,659,140	$54,362,088	—	31 Dec 2025	13F
BRAIDWELL LP	13F	Company	2.1%	1,634,615	$53,549,987	—	31 Dec 2025	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	2.1%	1,621,620	$53,124,271	—	31 Dec 2025	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	2%	1,601,882	$52,479,000	—	31 Dec 2025	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	2%	1,549,284	$50,754,544	—	31 Dec 2025	13F
Paradigm Biocapital Advisors LP	13F	Company	1.9%	1,467,266	$48,067,634	—	31 Dec 2025	13F
Remedium Capital Partners, LLC	13F	Company	1.8%	1,456,231	$47,706,000	—	31 Dec 2025	13F
Affinity Asset Advisors, LLC	13F	Company	1.8%	1,432,591	$46,931,681	—	31 Dec 2025	13F
Venrock Healthcare Capital Partners III, L.P.	13D/G	—	4.6%	2,685,448	$40,335,429	$0	31 Dec 2024	13D/G
FRANKLIN RESOURCES INC	13F	Company	1.4%	1,109,274	$36,339,817	—	31 Dec 2025	13F
BAKER BROS. ADVISORS LP	13F 3/4/5	Company · Director	1.3%	1,000,000	$32,760,000	—	31 Dec 2025	13F 3/4/5
Cameron Turtle	3/4/5	Chief Executive Officer, Director	— mixed-class rows	1,155,540 mixed-class rows	$31,326,796	-$3,810,091	01 Apr 2026	3/4/5
Pictet Asset Management Holding SA	13F	Company	1.2%	913,960	$29,941,330	—	31 Dec 2025	13F
Siren, L.L.C.	13F	Individual	1%	818,598	$26,817,270	—	31 Dec 2025	13F
Polar Capital Holdings Plc	13F	Company	0.94%	740,326	$24,253,080	—	31 Dec 2025	13F
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	0.9%	710,626	$23,280,108	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.86%	680,566	$22,295,342	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13F	Company	0.84%	662,351	$21,698,619	—	31 Dec 2025	13F
EMERALD ADVISERS, LLC	13F	Company	0.81%	636,109	$20,838,931	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.73%	574,622	$18,824,617	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.71%	561,023	$18,379,115	—	31 Dec 2025	13F
Blackstone Inc.	13F	Company	0.64%	500,998	$16,412,694	—	31 Dec 2025	13F
S.c.a. Candriam	13F	Individual	0.54%	425,534	$13,941,087	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.53%	419,727	$13,750,257	—	31 Dec 2025	13F
EMERALD MUTUAL FUND ADVISERS TRUST	13F	Company	0.52%	412,371	$13,509,274	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.35%	275,065	$9,011,129	—	31 Dec 2025	13F
Woodline Partners LP	13F	Company	0.34%	265,892	$8,710,622	—	31 Dec 2025	13F
Capital World Investors	13F	Company	0.25%	200,172	$6,557,635	—	31 Dec 2025	13F
ARMISTICE CAPITAL, LLC	13F	Company	0.25%	196,426	$6,434,916	—	31 Dec 2025	13F
Bank of New York Mellon Corp	13F	Company	0.24%	192,830	$6,317,104	—	31 Dec 2025	13F
HighVista Strategies LLC	13F	Company	0.24%	188,206	$6,165,629	—	31 Dec 2025	13F
SILVERARC CAPITAL MANAGEMENT, LLC	13F	Company	0.24%	187,737	$6,150,264	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.23%	182,734	$5,986,378	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.23%	182,524	$5,979,487	—	31 Dec 2025	13F
Universal- Beteiligungs- und Servicegesellschaft mbH	13F	Individual	0.22%	171,211	$5,608,873	—	31 Dec 2025	13F
Michael Thomas Henderson	3/4/5	Director	— mixed-class rows	193,606 mixed-class rows	$5,523,583	—	21 Jan 2026	3/4/5

Recent Insider Transactions by Companies or Individuals for Spyre Therapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Cameron Turtle	SYRE	Common Stock	Sale	-2.33%	$739,912	$49.33	-15,000	627,540	01 Apr 2026	Direct
Sheldon Sloan	SYRE	Common Stock	Sale	-100%	$397,900	$50.00	-7,958	0	01 Apr 2026	Direct
Sheldon Sloan	SYRE	Common Stock	Options Exercise				7,958	7,958	01 Apr 2026	Direct
Sheldon Sloan	SYRE	Stock Option (Right to Buy)	Options Exercise	-8.33%			-7,958	87,542	01 Apr 2026	Direct
Scott L. Burrows	SYRE	Common Stock	Sale	-7.11%	$370,076	$49.34	-7,500	97,994	01 Apr 2026	Direct
Scott L. Burrows	SYRE	Common Stock	Options Exercise	7.65%			7,500	105,494	01 Apr 2026	Direct
Scott L. Burrows	SYRE	Stock Option (Right to Buy)	Options Exercise	-1.86%			-7,500	394,857	01 Apr 2026	Direct
Scott L. Burrows	SYRE	Common Stock	Sale	-2.49%	$101,620	$40.65	-2,500	97,994	03 Mar 2026	Direct
Scott L. Burrows	SYRE	Common Stock	Options Exercise	2.55%			2,500	100,494	03 Mar 2026	Direct
Scott L. Burrows	SYRE	Stock Option (Right to Buy)	Options Exercise	-0.62%			-2,500	402,357	03 Mar 2026	Direct
Cameron Turtle	SYRE	Common Stock	Sale	-2.28%	$632,866	$42.19	-15,000	642,540	02 Mar 2026	Direct
Cameron Turtle	SYRE	Common Stock	Sale	-2.23%	$492,045	$32.80	-15,000	657,540	02 Feb 2026	Direct
Michael Thomas Henderson	SYRE	Common Stock	Other	60%			63,227	168,606	21 Jan 2026	Direct
Scott L. Burrows	SYRE	Stock Option (Right to Buy)	Award				140,000	140,000	09 Jan 2026	Direct
Cameron Turtle	SYRE	Stock Option (Right to Buy)	Award				528,000	528,000	09 Jan 2026	Direct
Sheldon Sloan	SYRE	Stock Option (Right to Buy)	Award				140,000	140,000	09 Jan 2026	Direct
Heidy King-Jones	SYRE	Stock Option (Right to Buy)	Award				140,000	140,000	09 Jan 2026	Direct
Cameron Turtle	SYRE	Common Stock	Sale	-2.18%	$460,134	$30.68	-15,000	671,907	02 Jan 2026	Direct
Cameron Turtle	SYRE	Common Stock	Sale	-2.14%	$435,356	$29.02	-15,000	686,907	01 Dec 2025	Direct
Cameron Turtle	SYRE	Common Stock	Sale	-6.02%	$1,049,778	$23.33	-45,000	701,907	03 Nov 2025	Direct
Scott L. Burrows	SYRE	Common Stock	Sale	-15.8%	$299,639	$16.26	-18,428	97,994	02 Sep 2025	Direct
Fairmount Funds Management LLC	SYRE	Stock Option (Right to Buy)	Award				25,000	25,000	29 May 2025	By Tomas Kiselak
Fairmount Funds Management LLC	SYRE	Stock Option (Right to Buy)	Award				25,000	25,000	29 May 2025	By Peter Harwin
Laurie Stelzer	SYRE	Stock Option (Right to Buy)	Award				25,000	25,000	29 May 2025	Direct
Sandra Milligan	SYRE	Stock Option (Right to Buy)	Award				25,000	25,000	29 May 2025	Direct
Mark C. McKenna	SYRE	Stock Option (Right to Buy)	Award				25,000	25,000	29 May 2025	Direct
Michael Thomas Henderson	SYRE	Stock Option (Right to Buy)	Award				25,000	25,000	29 May 2025	Direct
Jeffrey W. Albers	SYRE	Stock Option (Right to Buy)	Award				25,000	25,000	29 May 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.